2017 has started on a note of new growth, with the announcement of the accession of Biogen International GmbH to Britest Associate status.
A pioneer in biotechnology for over two decades, Biogen today is a global organization with more than 7,000 employees possessing the leading portfolio of medicines to treat multiple sclerosis, and is at the forefront of research into new medicines for neurological conditions and rare genetic disorders. Led by world-class research and development, Biogen uses novel science and leading-edge technologies to create, commercialize, and manufacture transformative therapies for patients with few or no treatment options.
Associateship provides a license to the use of an agreed set of Britest tools for Biogen employees who have undertaken Britest training. Welcoming the confirmation of Biogen's Associate status for 2017, Britest CEO Gareth Jenkins said;
This is excellent news with which to welcome the new year, and something that I hope will become a staging point for further developing our relationship with Biogen.
The development comes in the wake of a successful demonstration of value to Biogen in 2016, through a Britest facilitated four-day, end-to-end process review for a Biogen product which is dependent in part upon services provided by multiple Contract Manufacturing Organisations. Biogen's Associate Director of Manufacturing Science Cornelia Thieme said:
The study gave us immediate, valuable insight into an important product line for the business, and clear priorities for its development, but just as importantly helped our own international team understand how Britest can be used to foster communications and collaborative work across functions, time zones, and even across our supply chain.
Britest looks forward to working in support of colleagues at Biogen on the further implementation of Britest in the coming twelve months.
